New appointments at Lycera
This article was originally published in Scrip
Executive Summary
Lycera, a US company developing small-molecule pharmaceuticals to treat autoimmune diseases, has appointed Dr Paul Changelian and Dr Peter Toogood to its drug development team. Dr Changelian, previously director of inflammation biology at Pfizer, will serve as vice-president of biology, while Dr Toogood, who was an associate director and research fellow at Parke-Davis and Pfizer, becomes vice-president of chemistry and chemical biology.